Drug-drug interactions between warfarin and psychotropics: Updated review of the literature

Pharmacotherapy

Volumn 32, Issue 10, 2012, Pages 932-942

  Nadkarni, Ashwini ^a   Oldham, Mark A ^a   Howard, Mark ^b   Berenbaum, Isidore ^b  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Coumadin; Drug drug interactions; Psychosomatics; Psychotropics; Warfarin

Indexed keywords

AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORAL HYDRATE; CITALOPRAM; CLOZAPINE; DIAZEPAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HERBACEOUS AGENT; LITHIUM; MODAFINIL; NICOTINE; NORTRIPTYLINE; OXCARBAZEPINE; PAROXETINE; PROPRANOLOL; PSYCHOTROPIC AGENT; QUETIAPINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; TRAZODONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CLINICAL EFFECTIVENESS; CONGESTIVE HEART FAILURE; DAYTIME SOMNOLENCE; DEEP VEIN THROMBOSIS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; EPISTAXIS; HEART ARRHYTHMIA; HEART INFARCTION; HEMATEMESIS; HEMOSTASIS; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; INTESTINE HEMATOMA; LOADING DRUG DOSE; MELENA; NONHUMAN; PATIENT MONITORING; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TREATMENT INDICATION;

ANIMALS; ANTICOAGULANTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; PSYCHOTROPIC DRUGS; WARFARIN;

EID: 84867312317     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01119     Document Type: Review

References (76)

1. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-27.
2. Bachawati M. Anticoagulation and psychotropic medications. Curr Psychiatry Rep 2010;12:265-71.
3. Sayal KS, Duncan-McConnell DA, McConnell HW, et al. Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000;102:250-5.
4. Nadkarni A, Oldham M, Howard M, et al. Detrimental effects of divalproex on warfarin therapy following mechanical valve replacement. J Card Surg 2011;26:492-4.
5. Guthrie SK, Stoysich AM, Bader G, et al. Hypothesized interaction between valproic acid and warfarin. J Clin Psychopharmacol 1995;15:138-9.
6. Venkatakrishnan K, Obach S. Drug-drug Interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessments from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab 2007;8:449-62.
7. Tompkins LM, Wallace AD. Mechanisms of cytochrome P450 induction. J Biochem 2007;21:176-81.
8. Rolan P. Plasma protein binding displacement interactions - why are they still regarded as clinically important? Br J Clin Pharmac 1994;37:125-8.
9. Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. BMJ 2005;331:529-30.
10. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004;91:119-28.
11. Conley EL, Coley KC, Pollock BG, et al. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital. Pharmacotherapy 2001;21:1325-30.
12. Yap KB, Low ST. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J 1999;40:480-2.
13. Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy 1997;17:170-2.
14. Woolfrey S, Gammack NS, Dewar MS, et al. Fluoxetine-warfarin interaction. BMJ 1993;24:241.
15. Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions. II. J Clin Psychopharmacol 1990;10:213-7.
16. Ford MA, Anderson ML, Rindone JP, et al. Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin. J Clin Psychopharmacol 1997;17:110-2.
17. Brøsen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001;11:275-83.
18. Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 1997;44: 199-202.
19. Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997;32:37-42.
20. Wilner KD, Lazar JD, Asperloff G, et al. The effects of sertraline on the pharmacodynamics of warfarin in healthy volunteers. Biol Psychiatr 1991;29:354-5.
21. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation potential for interactions paroxetine with diazepam, cimetidine, warfarin. Acta Psychiatr Scand 1989;80:102-6.
22. Monastero R, Camarda R, Camarda C. Potential drug-drug interaction between duloxetine and acenocoumarol in a patient with Alzheimer's disease. Clin Ther 2007;29: 2706-9.
23. Glueck CJ, Khalil Q, Winiarska M, et al. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 2006;295:1517-8.
24. Chappell J, He J, Knadler MP, et al. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol 2009;49:1456-66.
25. Knadler MP, Lobo E, Chappell J, et al. Duloxetine: clinical pharmacokinetics and drug interactions. Clin Pharmacokinet 2011;50:281-94.
26. Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med 2009;41:619-28.
27. Jalili M, Dehpour AR. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega- 3 fatty acids. Arch Med Res, 2007;38:901-4.
28. Hardy JL, Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone. CMAJ 1986;135:1372.
29. Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother 2000;34:734-6.
30. Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol 1995;35:730-8.
31. Loomis CW, Racz WJ. Drug interactions of amitriptyline and nortriptyline with warfarin in the rat. Res Commun Chem Pathol Pharmacol 1980;30:41-58.
32. Pond SM, Graham GG, Birkett DJ, et al. Effects of tricyclic antidepressants on drug metabolism. Clin Pharmacol Ther 1975;18:191-9.
33. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007;151:737-48.
34. Henderson L, Yue QY, Bergquist C, et al. St. John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002;54:349-56.
35. Xuemin J, Williams KM, Liauw WS, et al. Effects of St. John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9.
36. Uygur Bayramiçli O, Kalkay MN, Oskay Bozkaya E, et al. St. John's wort (Hypericum perforatum) and warfarin: dangerous liaisons! Turk J Gastroenterol 2011;22:115.
37. Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol 1999;19:382-3.
38. Yang FW, Liang CS. Multiple intracerebral hemorrhages in an elderly patient after adding quetiapine to a stable warfarin regimen. Gen Hosp Psychiatry 2011;33:302.
39. Udall JA. Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 1975;35:67-71.
40. Orme M, Breckenridge A, Brooks RV. Interactions of benzodiazepines with warfarin. Br Med J 1972;9:611-4.
41. Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med 1986;80:41-51.
42. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine interaction. South Med J 1990;83:981.
43. Avent ML, Canaday BR, Sawyer WT. Warfarin-induced intramural hematoma of the small intestine. Clin Pharm 1992;11:632-5.
44. Kendall A, Boivin M. Warfarin-carbamazepine interaction. Ann Intern Me 1981;94:280.
45. Parrish RH, Pazdur DE, O'donnell PJ. Effect of carbamazepine initiation and discontinuation on antithrombotic control in a patient receiving warfarin: case report and review of the literature. Pharmacotherapy 2006;26:1650-3.
46. Ross JR, Beeley L. Interaction between carbamazepine and warfarin. Br Med J 1980;1:1415.
47. Herman D, Locatelli I, Grabnar I, et al. The influence of cotreatment with carbamazepine, amiodarone and statins on warfarin metabolism and maintenance dose. Eur J Clin Pharmacol 2006;62:291-6.
48. Massey EW. Effect of carbamazepine on coumadin metabolism. Ann Neurol 1983;13:691-2.
49. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994;35 (Suppl 3):S14-9.
50. Krämer G, Tettenborn B, Klosterskov Jensen P, et al. Oxcarbazepine does not affect the anticoagulant activity of warfarin. Epilepsia 1992;33:1145-8.
51. Yoon HW, Giraldo EA, Wijdicks EF. Valproic acid and warfarin: an underrecognized drug interaction. Neurocrit Care 2011;15:182-5.
52. Wen X, Wang JS, Kivistö KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001;52:547-53.
53. Kiang TK, Ho PC, Anari MR, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci 2006;94:261-71.
54. Panjehshahin MR, Bowmer CJ, Yates MS. Effect of valproic acid, its unsaturated metabolites and some structurally related fatty acids on the binding of warfarin and dansylsarcosine to human albumin. Biochem Pharmacol 1991;41:1227-33.
55. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging 2003;20:141-52.
56. Zeller JA, Schlesinger S, Runge U, et al. Influence of valproate monotherapy on platelet activation and hematologic values. Epilepsia 1999;40:186-9.
57. Robertson P Jr, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002;42:205-14.
58. Robertson P Jr, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003;42:123-37.
59. Scott AK, Park BK, Breckenridge AM. Interaction between warfarin and propranolol. Br J Clin Pharmaco 1984;17:559-64.
60. Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of interaction between smoking and warfarin: a systematic review and meta-analysis. Chest 2011;139:1130-9.
61. Schaffer SD, Yoon S, Zadezensky I. A review of smoking cessation: potentially risky effects on prescribed medications. J Clin Nurs 2009;18:1533-40.
62. Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004;76:178-84.
63. Zhang W, Ramamoorthy Y, Tyndale RF, et al. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos 2003;31:768-72.
64. Chin JL. Disulfiram and warfarin. Ann Intern Med 1973;79:288-9.
65. O'Reilly RA. Interaction of sodium warfarin and disulfiram (Antabuse) in man. Ann Intern Med 1973;78:73-6.
66. Rothstein E. Warfarin effect enhanced by disulfiram (Antabuse). JAMA 1972;221:1052-3.
67. Yamreudeewong W, Wong HK, Brausch LM, et al. Probable interaction between warfarin and marijuana smoking. Ann Pharmacother 2009;43:1347-53.
68. Tiseo PJ, Foley K, Friedhoff LT. The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998;46(suppl 1):45-50.
69. Reece PA, Garnett WR, Rock WL Jr, et al. Lack of effect of tacrine administration on the anticoagulant activity of warfarin. J Clin Pharmacol 1995;35:526-8.
70. Teichert M, Visser LE, Uitterlinden AG, et al. Selective serotonin reuptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol 2011;72:798-805.
71. Lilly USA, LLC. Cymbalta package insert. Indianapolis, IN; 2011. Available from pi.lilly.com/us/cymbalta-pi.pdf.
72. Novartis Pharmaceuticals Corp. Ritalin package insert. East Hanover, NJ; 2010. Available from www.pharma.us.novartis. com/product/pi/pdf/ritalin-ritalin- sr.pdf.
73. DSM Pharmaceuticals Inc. Adderall package insert. Greenville, NC; 2007. Available from www.accessdata.fda.gov/drugsatfda- docs/label/2007/011522s040lbl. pdf.
74. Berlowitz DR, Miller DR, Oliveria SA, et al. Differential associations of beta-blockers with hemorrhagic events for chronic heart failure patients on warfarin. Pharmacoepidemiol Drug Sa 2006;15:799-807.
75. Warrington SJ, Johnston A, Lewis Y, et al. Bisoprolol: studies of potential interactions with theophylline and warfarin in healthy volunteers. J Cardiovasc Pharmaco 1990;16(suppl 5): S164-8.
76. Faessel HM, Obach RS, Rollema H, et al. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet 2010;49: 799-816.